<DOC>
	<DOCNO>NCT02434497</DOCNO>
	<brief_summary>The purpose study evaluate safety Rosuvastatin Children Adolescents Homozygous Familial Hypercholesterolemia .</brief_summary>
	<brief_title>A Study Evaluate Safety Rosuvastatin Children Adolescents With Homozygous Familial Hypercholesterolemia</brief_title>
	<detailed_description>This long-term extension ( LTE ) randomize , double-blind , cross-over study rosuvastatin 20 mg daily ( QD ) versus placebo QD child adolescent ( age 6 &lt; 18 year ) homozygous familial hypercholesterolemia ( HoFH ) ( Study D3561C00004 ) . The study design ass long-term safety tolerability rosuvastatin 20 mg pediatric patient HoFH . In study patient receive rosuvastatin 20 mg QD . Investigators also permit titrate dose rosuvastatin 20 40 mg per day feel warrant aggressively treat patient ' elevate LDL-C level . This up-titration permitted Asian patient . Pharmacokinetic data trough plasma exposure rosuvastatin also assess pediatric patient HoFH take daily dose rosuvastatin 40 mg . The primary outcome measure assess include 1 ) Adverse event , include : - The frequency severity adverse event , - Rate discontinuation due adverse event , - Abnormal serum urine laboratory value , electrocardiogram ( ECGs ) , physical examination , vital sign ; 2 ) Assessments growth .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Prior study relate procedure perform , provision write informed consent parent/both parent guardian statement assent child adolescent ( require Institutional Review Board [ IRB ] Independent Ethics Committee [ IEC ] accord local regulation guideline ) . Study D3561C00004 participant 18th birthday ( adult ) require provide write informed consent . Communication take place Investigator , patient/guardian child/adolescent confirm understanding require compliance requirement study . 2 . Male female child adolescent age 6 &lt; 18 year onset Study D3561C00004 ( even 18th birthday study ) : Documentation genetic test confirm 2 mutated allele LDL receptor gene locus ; and/or Documented untreated LDL C &gt; 500 mg/dL ( 12.9 mmol/L ) TG &lt; 400 mg/dL ( 4.5 mmol/L ) least 1 follow criterion : Tendinous and/or cutaneous xanthoma prior 10 year age ; Documentation HeFH parent : genetic and/or clinical criterion 3 . Negative pregnancy test ( b human chorionic gonadotropin analysis ) prior baseline female child bear potential : Female patient child bear potential must adhere pregnancy prevention method ( abstinence , chemical , mechanical ) study 3 month follow last dose ; Male patient refrain father child ( include sperm donation ) study 3 month follow last dose ; 4 . Were take study drug end Study D3561C00004 willing follow study procedure include adherence dietary guideline , study visit , fast blood draw , compliance study treatment regimen . 1 . History statin induct myopathy serious hypersensitivity reaction HMG CoA reductase inhibitor ( statin ) , include rosuvastatin , Visit 1 Study D3561C00004 . 2 . Fasting serum glucose &gt; 9.99 mmol/L ( 180 mg/dL ) glycosylated hemoglobin &gt; 9 % Study D3561C00004 patient history diabetic ketoacidosis within past year . 3 . Uncontrolled hypothyroidism define thyroid stimulate hormone &gt; 1.5 time upper limit normal ( ULN ) time Study D3561C00004 . 4 . Evidence active liver disease hepatic dysfunction ( except confirm diagnosis Gilbert 's disease ) define nontransient elevation ALT AST elevation ≥3 time ULN nontransient total bilirubin ≥2 time ULN Study D3561C00004 . 5 . Definite suspect personal history family history clinically significant adverse drug reaction ( ADRs ) , hypersensitivity drug similar chemical structure rosuvastatin well statins .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>LDL-C</keyword>
	<keyword>HoFH</keyword>
	<keyword>Hyperlipidemia</keyword>
</DOC>